Revenue segments as reported by the company.

Companion Animal

Livestock

Contract Manufacturing & Human Health

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Interest expense

Other (income)/deductions–net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Zoetis

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products, biodevices, genetic tests, and precision livestock farming technology. The firm operates through the following segments: United States & International. Its products include vaccines, parasiticides, anti-infectives, dermatology products, medicated feed additives, animal health diagnostics, and other pharmaceutical products for both companion animal and livestock customers. The company was founded in 1952 and is headquartered in Parsippany, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zoetis reports robust 2022 results, eyes growth in key markets

Zoetis delivered strong financial performance in 2022 and projects continued growth in 2023. The company's investments in R&D, CapEx, and customer engagement strategies position it well for future competition. Challenges from inflation, competition, and supply chain issues require careful navigation, but opportunities in key growth areas offer potential for sustained success.

Zoetis reports solid Q1 results, reaffirms full-year guidance

Zoetis delivered solid Q1 results despite challenges in certain segments. The company remains optimistic about future growth opportunities, supported by upcoming product launches and strategic investments. Investor Day will provide detailed insights into Zoetis' growth strategy and innovation pipeline.

Zoetis reports robust Q2 earnings, eyes global market expansion

Zoetis delivered strong financial results in Q2 2023, with expectations of continued growth in operational revenue and adjusted net income for the full year. The company remains focused on driving revenue growth through industry tailwinds and innovation over the next few years.

Zoetis reports robust Q3 performance and anticipates accelerated growth

Zoetis' Q3 2023 performance reflects strong revenue and income growth, supported by successful product launches and a robust diagnostics portfolio.
While facing challenges from upcoming competition and margin pressures, the company remains confident in its growth prospects for 2023 and 2024.
Opportunities lie in accelerated growth driven by key products, macro trends in animal health, and ongoing investments in innovation and cost management.
Overall, Zoetis' strategic strengths position it well to navigate challenges and capitalize on opportunities for sustained growth and value creation.

Zoetis reports robust 2023 results and sets sights on international growth

Zoetis delivered strong financial performance in 2023, driven by innovative products and operational growth across portfolios. The company is well-positioned for continued growth in 2024, focusing on innovation, market leadership, and addressing challenges like currency dynamics and capacity constraints. Opportunities lie in international markets, DTC initiatives, and sustained revenue growth.

Zoetis excels in Q1 with double-digit growth and strategic focus

Zoetis' Q1 performance reflects strong revenue and income growth, driven by successful product launches and market leadership. The company's focus on innovation, quality, and strategic divestments positions it well for future growth. Challenges in livestock and competition require strategic adaptation, while opportunities in product growth and market expansion offer promising avenues for development.

Zoetis excels in Q2 2024, raises guidance and announces buyback

Zoetis' Q2 2024 performance highlights its strong market position, driven by innovative products and strategic initiatives. While challenges exist in the competitive landscape, the company's focus on customer-centric innovation and financial strength position it well for future growth. With raised guidance and shareholder value initiatives, Zoetis is poised for continued success in the animal health industry.

Zoetis reports strong Q3 earnings and eyes sustained growth

Zoetis delivered robust operational growth in Q3 2024, driven by strong performance in key segments and products, leading to a revised full year guidance and confidence in future prospects.
Despite potential challenges in navigating a dynamic landscape and supply chain efficiency, Zoetis remains well-positioned to capitalize on opportunities for growth in 2025 through innovation and market expansion.
With a focus on sustained above-industry average growth, Zoetis' strategic strengths in key franchises and market positioning reinforce their leadership in the animal health industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The firm operates through the United States and International geographical segments. The company was founded in 1952 and is headquartered in Parsippany, NJ.

Zoetis Inc. (NYSE:ZTS ) Jefferies London Healthcare Conference November 20, 2024 10:00 AM ET Company Participants Wetteny Joseph - CFO Conference Call Participants Glen Santangelo - Jefferies Glen Santangelo Thank you for taking the time to join us this afternoon. We're very excited to have Zoetis for our next presentation.

Zoetis Inc. (ZTS) Management presents at Jefferies London Healthcare Conference (Transcript)

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will participate in the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts at 11:30 a.m. ET. Investors and other interested parties will be able to access a live audio webcast of the session by visiting http://investor.zoetis.com/events-presentations. A replay will also be avai.

Zoetis to Participate in the Piper Sandler 36th Annual Healthcare Conference

Sandoz Group AG

Investors with an interest in Medical - Drugs stocks have likely encountered both Sandoz Group AG Sponsored ADR (SDZNY) and Zoetis (ZTS). But which of these two stocks offers value investors a better bang for their buck right now?

SDZNY vs. ZTS: Which Stock Should Value Investors Buy Now?

Zoetis, a leading animal health company, has shown impressive growth with a 17.55% CAGR since its IPO, outperforming the S&P 500. The company benefits from increasing global pet ownership and spending, making its revenues less susceptible to economic downturns. Zoetis boasts a strong competitive moat with a diverse product portfolio, significant patent protection, and consistent R&D investment.

Zoetis: This Beautifully Boring, Slow-Growing Compounder Is A Buy

Zoetis looks like a classic example of a premium business trading at a fair price following its recent dip.

1 Magnificent S&P 500 Dividend Stock Down 12% to Buy After Its Recent Pullback

PARSIPPANY, N. J.--(BUSINESS WIRE)--ZOETIS APPOINTS JAMIE BRANNAN TO NEWLY CREATED CHIEF COMMERCIAL OFFICER ROLE.

Zoetis Appoints Jamie Brannan to Newly Created Chief Commercial Officer Role

I reiterate a 'Buy' rating for Zoetis with a one-year target price of $210 per share, driven by strong product performance and strategic divestitures. The Company's osteoarthritis drugs, LIBRELA and SOLENSIA, delivered 97% operational revenue growth, with LIBRELA poised to become a $1 billion franchise. Zoetis projects 10–11% operational revenue growth and 13.5–14.5% adjusted net income growth for FY24, despite minor headwinds from China.

Zoetis Q3: Strong Osteoarthritis Pain Franchise

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will participate in the Jefferies London Healthcare Conference on Wednesday, November 20, 2024. Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts at 3:00 p.m. GMT. Investors and other interested parties will be able to access a live audio webcast of the session by visiting http://investor.zoetis.com/events-presentations. A replay will also be available.

Zoetis to Participate in Jefferies London Healthcare Conference

ZTS stock gains as third-quarter results beat both earnings and revenue estimates, driven by strong product sales. Management raises the 2024 outlook.

Zoetis Q3 Earnings & Revenues Beat, '24 Outlook Raised, Stock Up

Zoetis Inc. (NYSE:ZTS ) Q3 2024 Earnings Conference Call November 4, 2024 8:30 AM ET Company Participants Steve Frank - VP of IR Kristin Peck - CEO Wetteny Joseph - CFO Conference Call Participants Erin Wright - Morgan Stanley Michael Ryskin - Bank of America Brandon Vazquez - William Blair Jon Block - Stifel David Westenberg - Piper Sandler Balaji Prasad - Barclays Glen Santangelo - Jefferies Chris Schott - JPMorgan Chris LoBianco - TD Cowen Navann Ty - BNP Paribas Operator Welcome to the Third Quarter 2024 Financial Results Conference Call and Webcast for Zoetis. Hosting the call today is Steve Frank, Vice President of Investor Relations for Zoetis.

Zoetis Inc. (ZTS) Q3 2024 Earnings Call Transcript

Zoetis Inc (NYSE:ZTS, ETR:ZOE) delivered another impressive quarter, with revenue and earnings exceeding Wall Street estimates for the third quarter of fiscal year 2024. For the period ended September 30, 2024, the animal health company reported revenues of $2.39 billion, marking an 11% increase year-over-year from $2.15 billion in Q3 2023, and surpassing analyst expectations of $2.29 billion.

Zoetis raises full-year guidance on strong Q3 results

LOS ANGELES, CA / ACCESSWIRE / November 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors Are Invited To Join The Schall Law Firm In An Inquiry Into Zoetis Inc. For Fraud

Although the revenue and EPS for Zoetis (ZTS) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Compared to Estimates, Zoetis (ZTS) Q3 Earnings: A Look at Key Metrics

Zoetis raised its annual profit and revenue forecasts on Monday on strong demand for its medicines and vaccines for animals.

Zoetis raises annual forecasts on strong demand for pet treatments

Zoetis (ZTS) came out with quarterly earnings of $1.58 per share, beating the Zacks Consensus Estimate of $1.46 per share. This compares to earnings of $1.36 per share a year ago.

Zoetis (ZTS) Q3 Earnings and Revenues Beat Estimates

Zoetis beat third-quarter expectations and raised its outlook for the year. But Zoetis stock slips early Monday.

Zoetis Barks Up A Third-Quarter Beat And Raise, But Stock Slips

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today reported its financial results for the third quarter of 2024 and raised its full year 2024 guidance for revenue and adjusted EPS. The company reported revenue of $2.4 billion for the third quarter of 2024, an increase of 11% compared with the third quarter of 2023. On an operational1 basis, revenue for the third quarter of 2024 increased 14% compared with the third quarter of 2023. Net income for the third quarter of 2024 was $682.

Zoetis Announces Third Quarter 2024 Results

Accenture Plc

Amphenol

Domino's Pizza

Elevance Health Inc

Global Payments

Intuit

Lam Research

Mastercard

Microchip Technology

MSCI

Nordson

ResMed

Rollins

SPDR S&P 500 ETF Trust

UnitedHealth Group

Vanguard Dividend Appreciation ETF

The SPDR S&P 500 ETF Trust posted a loss of 0.89% in October, putting a pause on its strong run in 2024. The Top 15 dividend growth stocks for November 2024 offer an average dividend yield of 1.24% and appear to be about 23% undervalued based on dividend yield theory. Since its inception in September 2020, the watch list has achieved an 11.33% compound annual growth rate.

My Top 15 High-Growth Dividend Stocks For November 2024

LOS ANGELES, CA / ACCESSWIRE / November 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Zoetis Inc Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out

LOS ANGELES, CA / ACCESSWIRE / November 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors Are Invited To Join The Schall Law Firm In An Inquiry Into Zoetis Inc. For Securities Fraud

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Sandoz Group AG Sponsored ADR (SDZNY) and Zoetis (ZTS). But which of these two stocks offers value investors a better bang for their buck right now?

SDZNY or ZTS: Which Is the Better Value Stock Right Now?

Phibro Animal Health

TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) today announced the successful completion of the acquisition of the medicated feed additive product portfolio and certain water-soluble products from Zoetis Inc. (NYSE:ZTS). This acquisition marks a significant step in furthering Phibro's purpose to optimize global animal health and nutrition for better lives and a more sustainable world. “Adding this new lineup of medicated feed additives and water-soluble products.

Phibro Animal Health Corporation Completes Acquisition of Zoetis' Medicated Feed Additive Product Portfolio and Certain Water-Soluble Products

LOS ANGELES, CA / ACCESSWIRE / October 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Zoetis Inc Is Being Investigated For Violating Securities Laws And The Schall Law Firm Urges Affected Shareholders To Reach Out

LOS ANGELES, CA / ACCESSWIRE / October 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors Are Invited To Join The Schall Law Firm's Inquiry Into Zoetis Inc. For Securities Fraud

Besides Wall Street's top -and-bottom-line estimates for Zoetis (ZTS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.

News for Zoetis Stock (ZTS)